Latent TB Testing

Latent tuberculosis (TB) testing identifies immune evidence of infection in people without symptoms of active disease. It supports preventive treatment decisions, contact investigations, screening of people at elevated risk, and progress toward global TB-control objectives. The principal testing approaches are the tuberculin skin test (TST) and interferon-gamma release assays (IGRAs), with selection shaped by age, Bacille Calmette-Guérin (BCG) vaccination history, exposure risk, laboratory capacity, and national guidance.

The testing landscape is shifting toward targeted screening linked to clinical risk assessment and preventive therapy. Programs increasingly emphasize recent contacts, people living with HIV, individuals receiving immunosuppressive treatment, migrants from countries with higher TB incidence, and workers or residents in congregate settings. IGRAs offer logistical advantages where return visits for TST reading are difficult and are generally less affected by prior BCG vaccination, while TST remains important because it is inexpensive, widely familiar, and usable where laboratory infrastructure is limited. Integration with notification, contact tracing, radiography, and treatment follow-up is increasingly central to program performance.

Artificial intelligence (AI) is having its clearest near-term effect around latent TB testing rather than replacing immunological assays. Machine-learning tools can help prioritize screening from electronic health records, identify contacts or clinical groups needing evaluation, optimize laboratory workflows, and support interpretation of complex program data. AI-enabled chest-imaging systems may assist in ruling out active pulmonary TB before preventive treatment, but they do not establish latent infection by themselves. Effective deployment requires representative validation, human oversight, privacy safeguards, transparent performance monitoring, and controls against embedding unequal access or diagnostic bias.

North America generally combines established laboratory networks with targeted testing among contacts, healthcare workers, immigrants, and immunosuppressed patients. Europe has expanded coordinated TB prevention while managing differences in national screening policies and BCG practices. Asia-Pacific contains both high-burden settings requiring scalable, affordable workflows and advanced health systems with broader access to IGRAs. Latin America is balancing targeted screening with uneven laboratory and follow-up capacity. The Middle East faces mobility, displacement, and healthcare-access challenges that make continuity of screening and preventive treatment important. Africa carries a substantial TB burden and must connect testing with HIV services, contact investigation, reliable supply chains, and decentralized care.

ASEAN members face varied TB burdens, BCG policies, laboratory capabilities, and migrant-mobility patterns, making regionally consistent algorithms useful but not universally interchangeable. BRICS countries span major differences in epidemiology, health-system organization, and access to confirmatory services, so implementation needs locally validated pathways. The European Union benefits from shared technical resources while retaining national differences in screening and reimbursement. G7 systems generally have strong laboratory capacity but must address missed diagnoses in vulnerable populations and maintain high-quality contact investigation. GCC countries require approaches responsive to substantial expatriate populations and occupational or congregate-setting exposure. NATO members may benefit from interoperable occupational, military, and cross-border screening protocols that preserve clinical safeguards.

Australia, Canada, the United States, the United Kingdom, France, Germany, Italy, Spain, and Japan generally emphasize targeted testing, contact management, and screening of groups at increased risk, with choices between TST and IGRA influenced by clinical guidance and BCG history. Brazil, China, India, Mexico, Russia, and South Korea must align testing with substantial or historically significant TB-control needs, while addressing regional variation, laboratory access, and continuity of preventive treatment. Across all listed countries, effective practice depends on distinguishing latent infection from active disease, ensuring timely test reading or laboratory reporting, documenting exposure and treatment history, and linking positive results to appropriate clinical evaluation rather than treating a test result in isolation.

Industry and health-system leaders should define testing algorithms by risk group, age, BCG status, exposure history, and available capacity rather than adopting a single universal assay. They should pair testing with symptom review, appropriate evaluation for active TB, radiography or molecular testing when indicated, and clear preventive-treatment referral pathways. Investment priorities include quality assurance, staff training, specimen and reagent resilience, electronic result tracking, culturally competent outreach, and measurement of completion from screening through treatment initiation. AI should be introduced only after governance, validation, cybersecurity, and equity requirements are established, with ongoing review against real-world outcomes.

This executive summary is based on a structured review of authoritative public-health guidance and peer-reviewed evidence concerning latent TB infection, TST, IGRAs, risk-based screening, contact investigation, preventive treatment, laboratory operations, and digital decision support. Findings were synthesized comparatively across North America, Latin America, Europe, the Middle East, Africa, and Asia-Pacific, and across the specified country and international groupings. The assessment prioritizes recommendations and evidence that are clinically interpretable, geographically relevant, and applicable to implementation. Because policies and evidence evolve, local guidelines, product instructions, epidemiological data, and regulatory requirements should be checked before operational decisions.

Latent TB testing is most effective when it is part of an end-to-end prevention pathway rather than a standalone laboratory event. TST and IGRAs each have appropriate roles, and the strongest choice depends on patient risk, BCG history, return-visit feasibility, laboratory capacity, and national policy. Regional and country differences make adaptable algorithms essential. Leaders who connect targeted screening with active-disease exclusion, preventive-treatment access, quality assurance, and carefully governed digital tools can improve the likelihood that detected infection translates into meaningful TB prevention.